Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
PLx Pharma
Each group will be treated with either an immediate-release aspirin tablet or PL2200 capsule at 325 mg per day for 6 weeks, and evaluated via an endoscope for any gastrointestinal injury that may have been caused by study medication.
Age
50–75
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy volunteers, ≥50 and ≤75 years of age.
No endoscopically observed baseline gastrointestinal lesions.
You may not be if
Baseline gastrointestinal lesions or abnormal screening/baseline laboratory parameters deemed clinically significant by the Investigator.
Significant history of substance abuse or uncontrolled acute or chronic medical illness.
Active H. pylori infection.
Current use of low-dose aspirin for cardioprevention, or other ulcerogenic medications, gastroprotective, or anti-platelet agents.
Hypersensitivity to aspirin or other NSAIDs.
Clareo Health | Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
